NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Want to cut your energy bills? Here’s how five experts are doing it 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
IRVINE, Calif., May 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 19, 2017 lead plaintiff motion deadline.
If you purchased TherapeuticsMD shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food & Drug Administration identified deficiencies in its NDA for TX-004HR. When this news was announced, TherapeuticsMD’s stock price fell materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
